- Home
- SKK vs RLYB Comparison
SKK vs RLYB Comparison
Compare SKK & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKK
- RLYB
- Stock Information
- Founded
- SKK 2013
- RLYB 2018
- Country
- SKK Singapore
- RLYB United States
- Employees
- SKK N/A
- RLYB N/A
- Industry
- SKK
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- SKK
- RLYB Health Care
- Exchange
- SKK NYSE
- RLYB Nasdaq
- Market Cap
- SKK 12.3M
- RLYB 13.3M
- IPO Year
- SKK 2024
- RLYB 2021
- Fundamental
- Price
- SKK $0.74
- RLYB $0.32
- Analyst Decision
- SKK
- RLYB Hold
- Analyst Count
- SKK 0
- RLYB 4
- Target Price
- SKK N/A
- RLYB $15.00
- AVG Volume (30 Days)
- SKK 76.7K
- RLYB 70.4K
- Earning Date
- SKK 02-14-2025
- RLYB 05-08-2025
- Dividend Yield
- SKK N/A
- RLYB N/A
- EPS Growth
- SKK N/A
- RLYB N/A
- EPS
- SKK N/A
- RLYB N/A
- Revenue
- SKK $8,631,000.00
- RLYB $848,000.00
- Revenue This Year
- SKK N/A
- RLYB N/A
- Revenue Next Year
- SKK N/A
- RLYB N/A
- P/E Ratio
- SKK N/A
- RLYB N/A
- Revenue Growth
- SKK N/A
- RLYB N/A
- 52 Week Low
- SKK $0.61
- RLYB $0.22
- 52 Week High
- SKK $11.45
- RLYB $2.00
- Technical
- Relative Strength Index (RSI)
- SKK N/A
- RLYB 43.98
- Support Level
- SKK N/A
- RLYB $0.29
- Resistance Level
- SKK N/A
- RLYB $0.32
- Average True Range (ATR)
- SKK 0.00
- RLYB 0.02
- MACD
- SKK 0.00
- RLYB 0.01
- Stochastic Oscillator
- SKK 0.00
- RLYB 75.25
About SKK SKK HOLDINGS LIMITED
SKK Holdings Ltd is a civil engineering service provider that specializes in subsurface utility works in Singapore. It construct and maintain various public works and infrastructure projects that serve the society and the environment. Its projects are primarily the subsurface work related to projects undertaken by the Public Utilities Board (PUB) and Singapore Telecommunications Limited. The nature of these projects is related to repairing of pumping mains, sewer maintenance and pipe cable laying.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.